SCHEMBL7873207

SCHEMBL7873207

CNC(N)=NC(=O)c1cc2c(OC)cc(OCCCN3CCCC3)cc2[nH]1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD3 P35462 3/20 0.41
DRD2 P14416 3/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
EHMT2 Q96KQ7 3/20 0.40
EHMT1 Q9H9B1 3/20 0.40
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
KMT2A Q03164 2/20 0.40
HRH3 Q9Y5N1 3/20 0.40
LMNA P02545 1/20 0.40
HTR1A P08908 1/20 0.40
ADRA2A P08913 1/20 0.40
CYP2D6 P10635 1/20 0.40
ADRA2C P18825 1/20 0.40
OPRK1 P41145 1/20 0.40
KCNH2 Q12809 1/20 0.40
EBP Q15125 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
FLT3 P36888 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7877830 0.95 DRD3 (0.46) DRD3DRD2POLBKDM4EKMT2A
SCHEMBL7879778 0.90 ULK1 (0.45) DRD2HRH3MAOB
SCHEMBL7952496 0.89 FLT3 (0.43) DRD3DRD2POLBMAPTKDM4E
SCHEMBL7884761 0.86 AURKA (0.39) POLBMAPTKDM4EALDH1A1KMT2A
SCHEMBL7873297 0.86 ULK1 (0.45) DRD3DRD2KDM4EFLT3
SCHEMBL7873365 0.86 HDAC3 (0.42) DRD3DRD2POLBMAPTKDM4E
Hydrochloric Acid SCHEMBL7881226 0.85 HDAC3 (0.41) DRD3DRD2POLBMAPTKDM4E
SCHEMBL7881025 0.85 KMT2A (0.41) DRD3DRD2POLBMAPTKDM4E
SCHEMBL7882051 0.84 FLT3 (0.48) DRD3DRD2KDM4EKMT2AFLT3
SCHEMBL7879718 0.83 FLT3 (0.54) DRD3DRD2HRH3FLT3MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed